Mind Medicine (MindMed) Past Earnings Performance
Past criteria checks 0/6
Mind Medicine (MindMed)'s earnings have been declining at an average annual rate of -21.2%, while the Pharmaceuticals industry saw earnings growing at 1% annually.
Key information
-21.2%
Earnings growth rate
4.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -122.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Apr 04Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20MindMed regains compliance with Nasdaq's minimum bid price listing requirement
Sep 14MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value
Sep 04Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
Aug 26Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder
Aug 24MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps
Aug 18Mind Medicine GAAP EPS of -$0.04 beats by $0.01
Aug 11Mind Medicine announces 1-for-15 reverse stock split
Aug 04MindMed: Another Psychedelic Medicine Play Trading At A Potential Discount
Jul 12Mind Medicine: It's Best To Stay Far Away From This Risky Psychedelic Stock
Apr 20MindMed: Falling Uncontrollably
Jan 27Revenue & Expenses BreakdownBeta
How Mind Medicine (MindMed) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -96 | 42 | 52 |
| 30 Sep 23 | 0 | -77 | 36 | 49 |
| 30 Jun 23 | 0 | -75 | 37 | 44 |
| 31 Mar 23 | 0 | -63 | 30 | 39 |
| 31 Dec 22 | 0 | -57 | 30 | 36 |
| 30 Sep 22 | 0 | -69 | 32 | 38 |
| 30 Jun 22 | 0 | -69 | 31 | 39 |
| 31 Mar 22 | 0 | -98 | 60 | 38 |
| 31 Dec 21 | 0 | -93 | 59 | 35 |
| 30 Sep 21 | 0 | -89 | 59 | 32 |
| 30 Jun 21 | 0 | -80 | 53 | 29 |
| 31 Mar 21 | 0 | -41 | 19 | 24 |
| 31 Dec 20 | 0 | -34 | 14 | 19 |
| 30 Sep 20 | 0 | -29 | 11 | 14 |
Quality Earnings: MNMD is currently unprofitable.
Growing Profit Margin: MNMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MNMD is unprofitable, and losses have increased over the past 5 years at a rate of 21.2% per year.
Accelerating Growth: Unable to compare MNMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MNMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: MNMD has a negative Return on Equity (-122.52%), as it is currently unprofitable.